Glaukos' intraocular implant NDA filing accepted by FDA

15 December 2023

Shares in Glaukos Corporation (NYSE: GKOS) closed more than 25% higher on Thursday.

Glaukos earlier announced that the US Food and Drug Administration (FDA) had approved its New Drug Application (NDA) for a single administration per eye of iDose TR (travoprost intracameral implant) 75mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in ocular hypertension or open-angle glaucoma.

"A significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago"Thomas Burns is chairman and chief executive of the Californian firm, which is focused on developing new therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK